• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Japan Companion Diagnostics Oncology Market

    ID: MRFR/MED/48453-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Japan Companion Diagnostics Oncology Market Research Report By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry), By Applications (Therapeutic Monitoring, Patient Stratification, Predictive Testing, Disease Diagnosis), By End-user (Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies), and By Test Type (Genetic Tests, Protein Biomarker Tests, MicroRNA Tests, Pathological Analysis)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Japan Companion Diagnostics Oncology Market Research Report- Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Japan Companion Diagnostics Oncology Market Summary

    The Japan Companion Diagnostics Oncology market is projected to grow significantly from 214.1 million USD in 2024 to 571.9 million USD by 2035.

    Key Market Trends & Highlights

    Japan Companion Diagnostics Oncology Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 9.34 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 571.9 million USD, indicating robust growth potential.
    • In 2024, the market is valued at 214.1 million USD, reflecting the current investment landscape in oncology diagnostics.
    • Growing adoption of personalized medicine due to increasing demand for targeted therapies is a major market driver.

    Market Size & Forecast

    2024 Market Size 214.1 (USD Million)
    2035 Market Size 571.9 (USD Million)
    CAGR (2025-2035) 9.34%

    Major Players

    Illumina, Exact Sciences, Laboratory Corporation of America, Merck, Bristol-Myers Squibb, Myriad Genetics, F. Hoffmann-La Roche, NeoGenomics, Thermo Fisher Scientific, Agilent Technologies, Celerion, Amgen, Roche, Abbott, Qiagen

    Japan Companion Diagnostics Oncology Market Trends

    Significant changes in the Japan Companion Diagnostics Oncology Market are being influenced by both regulatory support and technology advancements. The rising incidence of cancer in Japan, which has increased demand for specialized treatment methods, is one of the main market drivers. The Japanese government has made cancer treatment a top priority, including precision medicine into healthcare regulations and creating an atmosphere that is conducive to the advancement of companion diagnostics.

    This active participation promotes market investment and innovation. Collaboration between pharmaceutical and biotechnology businesses has increased recently with the goal of creating efficient companion diagnostics. This tendency makes it easier to find particular biomarkers, allowing for individualized treatment based on each patient's needs. This tendency has been further accelerated by the development of next-generation sequencing technologies, which enable more thorough genetic analyses that are essential for pinpointing treatments.

    The Japanese market is full of opportunities, particularly as the country's population ages and the demand for specialized cancer diagnostics rises. Companion diagnostics could become more widely used in standard clinical practice as patients and healthcare professionals become more aware of precision medicine. Furthermore, developments in artificial intelligence are being investigated to increase the precision and effectiveness of diagnostic procedures; this field has the potential to completely transform oncology diagnostic procedures.

    In conclusion, cooperative innovation, favorable government policies, and an increasing focus on precision medicine define the Japan Companion Diagnostics Oncology Market. These elements combine to produce a dynamic environment that offers many chances for system innovation and growth in the cancer treatment industry.

    Japan Companion Diagnostics Oncology Market Drivers

    Market Segment Insights

    Companion Diagnostics Oncology Market Technology Insights

    The Technology segment of the Japan Companion Diagnostics Oncology Market is pivotal in enhancing personalized medicine approaches by enabling precise diagnosis and treatment plans. Key technologies employed include Next Generation Sequencing, which has revolutionized genomic analysis by allowing swift sequencing of various genomes, thereby facilitating tailored therapies in oncology. This adaptation is integral for identifying specific genetic mutations that drive cancer progression, hence improving treatment outcomes through targeted therapies.

    Additionally, Polymerase Chain Reaction plays a critical role in amplifying small segments of DNA, making it highly valuable for detecting specific mutations and patient stratification. Furthermore, In Situ Hybridization is significant for localizing genetic material within tissue cells, providing crucial insights into tumor localization and characteristics by visualizing specific nucleic acid sequences.

    This technique supports the diagnostic process by providing spatial understanding of cancerous tissues. Immunohistochemistry remains a dominant method for determining protein expression in tissues, which aids in the classification of tumors and selecting appropriate therapies.

    In Japan, with a growing emphasis on precision medicine, these technologies are expected to lead to substantial advancements in diagnosis and therapeutic strategies, ultimately contributing to better patient management and outcomes in oncology. The landscape of the Japan Companion Diagnostics Oncology Market is primarily shaped by innovations in these technologies, supported by robust Research and Development initiatives aimed at enhancing cancer diagnostic capabilities, which is critical in a country that profoundly values advancements in healthcare.

    Each technology not only enhances diagnostic accuracy and therapeutic efficacy but also paves the way for innovative treatments tailored to the genetic makeup of individual patients, thus representing a significant evolution in the oncology care paradigm within Japan.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Companion Diagnostics Oncology Market Applications Insights

    The Japan Companion Diagnostics Oncology Market focuses significantly on various applications that enhance treatment efficiency and personalization in oncology. Therapeutic Monitoring plays a crucial role in assessing the effectiveness of treatments, allowing for timely adjustments, thus improving patient outcomes. Patient Stratification ensures tailored therapies for distinct patient groups, which is vital as the Japanese healthcare system increasingly emphasizes personalized medicine. Predictive Testing helps in identifying the likelihood of response to specific therapies, making it indispensable for clinicians seeking to optimize treatment plans.

    Disease Diagnosis is essential for determining the presence and type of cancer, and its advancements in Japan have contributed to early detection efforts. Overall, these applications collectively drive the Japan Companion Diagnostics Oncology Market forward by addressing the specific needs of oncology patients and streamlining treatment processes within the healthcare framework. The public health policies in Japan increasingly support these applications, further enhancing their significance in improving treatment success rates and advancing cancer management strategies.

    As a result, innovative solutions within these application areas hold substantial importance, paving the way for a more targeted approach to cancer care and contributing to improved health outcomes across the nation.

    Companion Diagnostics Oncology Market End-user Insights

    The End-user segment of the Japan Companion Diagnostics Oncology Market plays a pivotal role in the overall landscape of oncology diagnostics. Hospitals are essential as they provide critical patient care and access to a broad range of diagnostic tests, making them significant players in the market. Diagnostic Laboratories play a crucial role by offering specialized testing services that support clinical decision-making, thereby enhancing the overall treatment process. Research Institutions are vital for advancing the field, as they facilitate innovative studies that drive the development of targeted therapies and personalized medicine.

    Pharmaceutical Companies are key contributors as they utilize companion diagnostics to ensure that therapies are matched with the patients most likely to benefit from them. As the market continues to evolve, demand in these segments is expected to grow, fueled by technological advancements, increasing prevalence of cancer, and rising emphasis on personalized medicine. The integration of companion diagnostics into oncology practices enhances treatment efficacy and paves the way for improved patient outcomes, thereby solidifying their importance within the Japan Companion Diagnostics Oncology Market.

    The overall market growth is also propelled by the ongoing collaboration between healthcare providers and diagnostic firms to establish comprehensive cancer management solutions, thus emphasizing the interdependent relationship among these End-users.

    Companion Diagnostics Oncology Market Test Type Insights

    The Japan Companion Diagnostics Oncology Market, with a focus on Test Type, presents a diverse landscape of diagnostic options vital for personalized cancer treatment. Genetic Tests are crucial, as they help determine an individual's genetic predisposition to various cancers and guide treatment plans. Protein Biomarker Tests play a significant role by identifying specific proteins associated with cancer, enabling targeted therapies that improve patient outcomes. MicroRNA Tests are gaining traction due to their ability to provide insights into cancer progression and response to treatments, showcasing their importance in real-time therapy adjustments.

    Pathological Analysis remains a cornerstone of oncology diagnostics, offering detailed examination of tissues for accurate cancer classification, which directly influences treatment strategies. This segmentation continues to evolve, driven by advancements in technology and increasing emphasis on personalized medicine, addressing the unique needs of patients in Japan's healthcare system. The government and healthcare institutions in Japan actively encourage research and development, promoting innovation in these test types to enhance cancer management and improve patient outcomes across the nation.

    Get more detailed insights about Japan Companion Diagnostics Oncology Market Research Report- Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The competitive landscape of the Japan Companion Diagnostics Oncology Market reflects a rapidly evolving sector poised for significant growth driven by advancements in precision medicine and personalized therapies. As a critical segment of oncology care, companion diagnostics provide essential tools for healthcare providers to identify the most effective treatment options tailored to individual patient profiles. With an increasing awareness of targeted therapies, there is a growing need for accurate and reliable diagnostic solutions that assist clinicians in making informed treatment decisions.

    Competitive dynamics are characterized by both established players and emerging biotech companies striving to enhance their offerings and improve patient outcomes. Collaboration between diagnostic companies and pharmaceutical organizations is also common, as they seek to develop and commercialize innovative treatments alongside corresponding diagnostic tests.

    Illumina

    Illumina has established a strong presence in the Japan Companion Diagnostics Oncology Market, predominantly known for its innovative sequencing technologies and genomic solutions that facilitate personalized cancer treatment. The company's strengths lie in its advanced genomic platforms that enable comprehensive analyses of the genetic underpinnings of various cancers. A focus on collaboration with clinical laboratories and healthcare providers enhances Illumina's positioning as it leverages its capabilities to support biomarker discovery and validation.

    Moreover, the company's commitment to continual technological advancements and streamlined processes positions it favorably to meet the evolving demands of oncologists and patients in Japan. As precision medicine becomes increasingly integrated into oncology practices, Illumina's infrastructure and expertise in next-generation sequencing serve to reinforce its competitive advantage in the market. As of May 27, 2025, Illumina's TruSight Oncology Comprehensive test received approval in Japan from the Ministry of Health, Labour and Welfare, further expanding access to precision cancer care.

    Exact Sciences

    Exact Sciences, another significant player in the Japan Companion Diagnostics Oncology Market, brings a suite of time-sensitive diagnostic solutions aimed at early cancer detection and treatment monitoring. The company is renowned for its expertise in molecular diagnostics, which includes non-invasive testing options that empower clinicians with timely insights into patient conditions.

    With a strategic focus on enhancing diagnostic accuracy and patient accessibility, Exact Sciences has cultivated strong relationships within the Japanese healthcare ecosystem, fostering collaboration with medical professionals and research institutions. The company actively engages in mergers and acquisitions to expand its product portfolio and amplify its footprint in the oncology diagnostics realm. Its key products are tailored to address prominent cancer types prevalent within the Japanese population, demonstrating an alignment with local healthcare needs and regulatory frameworks.

    Through innovative solutions and strategic partnerships, Exact Sciences continues to carve out a significant share of the competitive landscape in Japan's companion diagnostics oncology market.

    Key Companies in the Japan Companion Diagnostics Oncology Market market include

    Industry Developments

    In recent developments in the Japan Companion Diagnostics Oncology Market, Illumina has continued to strengthen its position through partnerships aimed at enhancing precision medicine initiatives. The market is witnessing significant growth as companies like F. Hoffmann-La Roche and Bristol-Myers Squibb are actively investing in targeted therapies, leveraging companion diagnostics to improve patient outcomes. Notably, in February 2023, Merck announced a collaboration with Myriad Genetics to advance precision oncology, focusing on biomarker development. Additionally, Thermo Fisher Scientific launched new solutions tailored for Japanese healthcare providers, further expanding market access.

    In terms of mergers and acquisitions, Laboratory Corporation of America made headlines in January 2023 with the acquisition of certain assets from NeoGenomics, aiming to enhance its genomic testing capabilities within Japan. The market's valuation has notably increased by 15% over the past two years, primarily driven by the rising demand for personalized medicine. This aligns with Japan's efforts to advance genomic research and its integration into routine clinical practice, as emphasized by the Ministry of Health, Labour and Welfare's ongoing initiatives.

    Companies like Qiagen and Abbott are also enhancing their research and development efforts to tap into this growing market.

    Market Segmentation

    Companion Diagnostics Oncology Market End-user Outlook

    • Hospitals
    • Diagnostic Laboratories
    • Research Institutions
    • Pharmaceutical Companies

    Companion Diagnostics Oncology Market Test Type Outlook

    • Genetic Tests
    • Protein Biomarker Tests
    • MicroRNA Tests
    • Pathological Analysis

    Companion Diagnostics Oncology Market Technology Outlook

    • Next Generation Sequencing
    • Polymerase Chain Reaction
    • In Situ Hybridization
    • Immunohistochemistry

    Companion Diagnostics Oncology Market Applications Outlook

    • Therapeutic Monitoring
    • Patient Stratification
    • Predictive Testing
    • Disease Diagnosis

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 199.5(USD Million)
    MARKET SIZE 2024 214.12(USD Million)
    MARKET SIZE 2035 571.88(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 9.341% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Illumina, Exact Sciences, Laboratory Corporation of America, Merck, BristolMyers Squibb, Myriad Genetics, F. HoffmannLa Roche, NeoGenomics, Thermo Fisher Scientific, Agilent Technologies, Celerion, Amgen, Roche, Abbott, Qiagen
    SEGMENTS COVERED Technology, Applications, End User, Test Type
    KEY MARKET OPPORTUNITIES Growing personalized medicine demand, Increased biomarker research investment, Advancements in genomic technologies, Expanding regulatory approvals, Rising prevalence of cancer
    KEY MARKET DYNAMICS Increasing cancer prevalence, Technological advancements, Regulatory support, Growing personalized medicine demand, Rising healthcare expenditures
    COUNTRIES COVERED Japan

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the Japan Companion Diagnostics Oncology Market in 2024?

    The expected market size of the Japan Companion Diagnostics Oncology Market in 2024 is valued at 214.12 million USD.

    What is the projected market size of the Japan Companion Diagnostics Oncology Market by 2035?

    By 2035, the projected market size of the Japan Companion Diagnostics Oncology Market is expected to reach 571.88 million USD.

    What is the expected compound annual growth rate (CAGR) for the Japan Companion Diagnostics Oncology Market from 2025 to 2035?

    The expected CAGR for the Japan Companion Diagnostics Oncology Market from 2025 to 2035 is 9.341%.

    Which technology segment is expected to dominate the Japan Companion Diagnostics Oncology Market in 2024?

    The Immunohistochemistry segment is expected to dominate the Japan Companion Diagnostics Oncology Market in 2024, valued at 114.12 million USD.

    What will be the market value for Next Generation Sequencing technology in 2035?

    The market value for Next Generation Sequencing technology in the Japan Companion Diagnostics Oncology Market is projected to be 120.0 million USD in 2035.

    Who are the key players in the Japan Companion Diagnostics Oncology Market?

    Key players in the Japan Companion Diagnostics Oncology Market include Illumina, Exact Sciences, Laboratory Corporation of America, Merck, and Bristol-Myers Squibb.

    What is the projected market value for the Polymerase Chain Reaction technology segment in 2035?

    The projected market value for the Polymerase Chain Reaction technology segment in 2035 is 80.0 million USD.

    How much is the In Situ Hybridization technology expected to be valued at in 2035?

    The In Situ Hybridization technology is expected to be valued at 65.0 million USD in 2035.

    What are some of the growth drivers for the Japan Companion Diagnostics Oncology Market?

    The growth drivers for the Japan Companion Diagnostics Oncology Market include advancements in technologies and increased demand for personalized medicine.

    What will the market value for Immunohistochemistry be in 2035?

    The market value for the Immunohistochemistry segment in 2035 is expected to reach 306.88 million USD.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. Japan
    59. Companion Diagnostics Oncology Market, BY Technology (USD Million)
    60. Next
    61. Generation Sequencing
    62. Polymerase Chain Reaction
    63. In
    64. Situ Hybridization
    65. Immunohistochemistry
    66. Japan
    67. Companion Diagnostics Oncology Market, BY Applications (USD Million)
    68. Therapeutic
    69. Monitoring
    70. Patient Stratification
    71. Predictive
    72. Testing
    73. Disease Diagnosis
    74. Japan
    75. Companion Diagnostics Oncology Market, BY End User (USD Million)
    76. Hospitals
    77. Diagnostic
    78. Laboratories
    79. Research Institutions
    80. Pharmaceutical
    81. Companies
    82. Japan Companion Diagnostics
    83. Oncology Market, BY Test Type (USD Million)
    84. Genetic
    85. Tests
    86. Protein Biomarker Tests
    87. MicroRNA
    88. Tests
    89. Pathological Analysis
    90. Competitive Landscape
    91. Overview
    92. Competitive
    93. Analysis
    94. Market share Analysis
    95. Major
    96. Growth Strategy in the Companion Diagnostics Oncology Market
    97. Competitive
    98. Benchmarking
    99. Leading Players in Terms of Number of Developments
    100. in the Companion Diagnostics Oncology Market
    101. Key developments
    102. and growth strategies
    103. New Product Launch/Service Deployment
    104. Merger
    105. & Acquisitions
    106. Joint Ventures
    107. Major
    108. Players Financial Matrix
    109. Sales and Operating Income
    110. Major
    111. Players R&D Expenditure. 2023
    112. Company
    113. Profiles
    114. Illumina
    115. Financial
    116. Overview
    117. Products Offered
    118. Key
    119. Developments
    120. SWOT Analysis
    121. Key
    122. Strategies
    123. Exact Sciences
    124. Financial
    125. Overview
    126. Products Offered
    127. Key
    128. Developments
    129. SWOT Analysis
    130. Key
    131. Strategies
    132. Laboratory Corporation of
    133. America
    134. Financial Overview
    135. Products
    136. Offered
    137. Key Developments
    138. SWOT
    139. Analysis
    140. Key Strategies
    141. Merck
    142. Financial
    143. Overview
    144. Products Offered
    145. Key
    146. Developments
    147. SWOT Analysis
    148. Key
    149. Strategies
    150. BristolMyers Squibb
    151. Financial
    152. Overview
    153. Products Offered
    154. Key
    155. Developments
    156. SWOT Analysis
    157. Key
    158. Strategies
    159. Myriad Genetics
    160. Financial
    161. Overview
    162. Products Offered
    163. Key
    164. Developments
    165. SWOT Analysis
    166. Key
    167. Strategies
    168. F. HoffmannLa Roche
    169. Financial
    170. Overview
    171. Products Offered
    172. Key
    173. Developments
    174. SWOT Analysis
    175. Key
    176. Strategies
    177. NeoGenomics
    178. Financial
    179. Overview
    180. Products Offered
    181. Key
    182. Developments
    183. SWOT Analysis
    184. Key
    185. Strategies
    186. Thermo Fisher Scientific
    187. Financial
    188. Overview
    189. Products Offered
    190. Key
    191. Developments
    192. SWOT Analysis
    193. Key
    194. Strategies
    195. Agilent Technologies
    196. Financial
    197. Overview
    198. Products Offered
    199. Key
    200. Developments
    201. SWOT Analysis
    202. Key
    203. Strategies
    204. Celerion
    205. Financial
    206. Overview
    207. Products Offered
    208. Key
    209. Developments
    210. SWOT Analysis
    211. Key
    212. Strategies
    213. Amgen
    214. Financial
    215. Overview
    216. Products Offered
    217. Key
    218. Developments
    219. SWOT Analysis
    220. Key
    221. Strategies
    222. Roche
    223. Financial
    224. Overview
    225. Products Offered
    226. Key
    227. Developments
    228. SWOT Analysis
    229. Key
    230. Strategies
    231. Abbott
    232. Financial
    233. Overview
    234. Products Offered
    235. Key
    236. Developments
    237. SWOT Analysis
    238. Key
    239. Strategies
    240. Qiagen
    241. Financial
    242. Overview
    243. Products Offered
    244. Key
    245. Developments
    246. SWOT Analysis
    247. Key
    248. Strategies
    249. References
    250. Related
    251. Reports
    252. LIST
    253. OF ASSUMPTIONS
    254. Japan Companion Diagnostics Oncology Market
    255. SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD Billions)
    256. Japan
    257. Companion Diagnostics Oncology Market SIZE ESTIMATES & FORECAST, BY APPLICATIONS,
    258. 2035 (USD Billions)
    259. Japan Companion Diagnostics
    260. Oncology Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    261. Japan
    262. Companion Diagnostics Oncology Market SIZE ESTIMATES & FORECAST, BY TEST TYPE,
    263. 2035 (USD Billions)
    264. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    265. ACQUISITION/PARTNERSHIP
    266. LIST
    267. Of figures
    268. MARKET SYNOPSIS
    269. JAPAN
    270. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
    271. JAPAN
    272. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY APPLICATIONS
    273. JAPAN
    274. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY END USER
    275. JAPAN
    276. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY TEST TYPE
    277. KEY
    278. BUYING CRITERIA OF COMPANION DIAGNOSTICS ONCOLOGY MARKET
    279. RESEARCH
    280. PROCESS OF MRFR
    281. DRO ANALYSIS OF COMPANION DIAGNOSTICS
    282. ONCOLOGY MARKET
    283. DRIVERS IMPACT ANALYSIS: COMPANION DIAGNOSTICS
    284. ONCOLOGY MARKET
    285. RESTRAINTS IMPACT ANALYSIS: COMPANION
    286. DIAGNOSTICS ONCOLOGY MARKET
    287. SUPPLY / VALUE CHAIN: COMPANION
    288. DIAGNOSTICS ONCOLOGY MARKET
    289. COMPANION DIAGNOSTICS ONCOLOGY
    290. MARKET, BY TECHNOLOGY, 2025 (% SHARE)
    291. COMPANION DIAGNOSTICS
    292. ONCOLOGY MARKET, BY TECHNOLOGY, 2019 TO 2035 (USD Billions)
    293. COMPANION
    294. DIAGNOSTICS ONCOLOGY MARKET, BY APPLICATIONS, 2025 (% SHARE)
    295. COMPANION
    296. DIAGNOSTICS ONCOLOGY MARKET, BY APPLICATIONS, 2019 TO 2035 (USD Billions)
    297. COMPANION
    298. DIAGNOSTICS ONCOLOGY MARKET, BY END USER, 2025 (% SHARE)
    299. COMPANION
    300. DIAGNOSTICS ONCOLOGY MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    301. COMPANION
    302. DIAGNOSTICS ONCOLOGY MARKET, BY TEST TYPE, 2025 (% SHARE)
    303. COMPANION
    304. DIAGNOSTICS ONCOLOGY MARKET, BY TEST TYPE, 2019 TO 2035 (USD Billions)
    305. BENCHMARKING
    306. OF MAJOR COMPETITORS

    Japan Companion Diagnostics Oncology Market Segmentation

     

     

     

    • Companion Diagnostics Oncology Market By Technology (USD Million, 2019-2035)

      • Next Generation Sequencing
      • Polymerase Chain Reaction
      • In Situ Hybridization
      • Immunohistochemistry

     

    • Companion Diagnostics Oncology Market By Applications (USD Million, 2019-2035)

      • Therapeutic Monitoring
      • Patient Stratification
      • Predictive Testing
      • Disease Diagnosis

     

    • Companion Diagnostics Oncology Market By End User (USD Million, 2019-2035)

      • Hospitals
      • Diagnostic Laboratories
      • Research Institutions
      • Pharmaceutical Companies

     

    • Companion Diagnostics Oncology Market By Test Type (USD Million, 2019-2035)

      • Genetic Tests
      • Protein Biomarker Tests
      • MicroRNA Tests
      • Pathological Analysis

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027